Healthcare Fraud SchemesPHX-AFK-USNCT07217730
Healthcare Integrity & Anti-Fraud Enforcement
An observational study of Healthcare Fraud Schemes and Kickback Networks, run by Truway Health, Inc. at 1 site in United States.
Trial summary
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities
- What is being tested?
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1) and Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Oct 2025to 13 Oct 2034
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population consists of U.S. healthcare facilities identified through coalition-backed validator affidavits and whistleblower declarations. These facilities exhibit patterns of fraud, kickback schemes, and supply chain vulnerabilities. The population is monitored prospectively via smart contract triggers, DAO voting, and public dashboard metrics.
Who may be able to join
- Facility has documented billing, compliance, or procurement irregularities.
- Facility participates in coalition validator onboarding and SHA-256 protocol enrollment.
- Facility provides access to billing, procurement, and whistleblower-anchored datasets for auditing.
Who cannot join
- Facility refuses validator onboarding or coalition integration.
- Facility lacks traceable procurement or compliance records.
- Facility has no whistleblower declaration or validation artifact.
- Facility operates outside U.S. jurisdiction or coalition-recognized governance zones.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016
New York, New York, 10016
About this study
Official title: § PHX-AFK-US: Public Health Exchange Protocol for Anti-Fraud, Kickback Prevention & Secure Chain Integrity in U.S. Healthcare Facilities
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Read the detailed description
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures, Whistleblower Activation, Regulatory Escalation Pathways
- Being tested
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Keywords
- Healthcare Integrity, Anti-Fraud, Kickback Prevention, Secure Supply Chain, Validator Governance, Coalition Oversight, NFT Fiscal Instruments, Smart Contract Enforcement, DAO Voting, SHA-256 Notarization, Whistleblower Affidavits, Regulatory Escalation, Public Transparency, Audit Trail, Asset Freeze Logic, CMS / DOJ / OIG Complaints, Procurement Reform, Phantom Billing, Referral Schemes, Medical Device Provenance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Validator-Governed Reform & Regulatory Escalation ProtocolOther
Also called PHX-AFK-US Protocol
This intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based.
Coalition-Grade Validator Dashboard Module (CVDM-1)Device
Also called PHX-AFK-US Governance Terminal
The Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains.
Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)Drug
Also called CFPAT-1
The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains.
| Study group | Role | What they receive |
|---|---|---|
| Flagged Healthcare Facilities - Validator Oversight Cohort | This cohort consists of U.S. healthcare facilities identified through validator affidavits, whistleblower declarations, and coalition intelligence as exhibiting patterns of fraud, kickback schemes, or supply chain vulnerabilities. Facilities are enrolled into the PHX-AFK-US Protocol for prospective observation, reform enforcement, and regulatory escalation. Each facility is subject to smart contract triggers, DAO voting logic, and public dashboard transparency. No biospecimens are retained; all data is notarized via SHA-256 hash anchors and integrated into NFT fiscal declarations and validator ballot modules. Receives: Other: Validator-Governed Reform & Regulatory Escalation Protocol; Device: Coalition-Grade Validator Dashboard Module (CVDM-1); Drug: Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Fraudulent Billing and Kickback Incidents Across Enrolled Facilities
Description:
This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols.
Facilities are assessed using the Unified Impact Index derived from:
Historical billing anomalies
Validator audit results
Whistleblower declarations
SHA-256 hash-anchored incident reports
Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards.
Time Frame: Baseline to 12 Months Post-Validator Onboarding.
Measured: Baseline to 12 Months Post-Validator Onboarding
Secondary outcomes (1)
Change in Supply-Chain Traceability and Compliance Across Enrolled Facilities
This outcome measures change in traceability and regulatory compliance for pharmaceuticals, medical devices, and non-pharmaceutical supplies. Facilities are evaluated using:
Validator Traceability Score (VTS) composite metrics
NFT tagging for supply-chain nodes
Blockchain-based audit trails
Comparative analysis dashboards identifying gaps and escalation pathways for non-compliant entities
Measured: Baseline to 12 Months Post-Validator Onboarding
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2025
- Study start13 Oct 2025
- Primary completion13 Oct 2034 (estimated)
- Study completion13 Oct 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthcare Fraud SchemesStudies of the same condition, open and under way.
- More trials run by Truway Health, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Truway Health, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gavin C Solomon, President & CEO, Principal investigator, Truway Health, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07217730
- Sponsor's protocol ID
- PRS-HI-AFK-SC-US-101325-GS
- Acronym
- PHX-AFK-US
- Status last verified
- Nov 2026
- First submitted
- 13 Oct 2025
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- § PHX-AFK-US: Public Health Exchange Protocol for Anti-Fraud, Kickback Prevention & Secure Chain Integrity in U.S. Healthcare Facilities
- ClinicalTrials.gov ID
- NCT07217730
- Acronym / sponsor ID
- PHX-AFK-US / PRS-HI-AFK-SC-US-101325-GS
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures, Whistleblower Activation, Regulatory Escalation Pathways
- Keywords
- Healthcare Integrity, Anti-Fraud, Kickback Prevention, Secure Supply Chain, Validator Governance, Coalition Oversight, NFT Fiscal Instruments, Smart Contract Enforcement
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Truway Health, Inc.Industry (pharma, biotech, devices)
- Study start
- 13 Oct 2025 (actual)
- Primary completion
- 13 Oct 2034 (estimated)
- Study completion
- 13 Oct 2034 (estimated)
- First posted
- 16 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Detailed description
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Flagged Healthcare Facilities - Validator Oversight Cohort | – | Other: Validator-Governed Reform & Regulatory Escalation Protocol, Device: Coalition-Grade Validator Dashboard Module (CVDM-1), Drug: Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)This cohort consists of U.S. healthcare facilities identified through validator affidavits, whistleblower declarations, and coalition intelligence as exhibiting patterns of fraud, kickback schemes, or supply chain vulnerabilities. Facilities are enrolled into the PHX-AFK-US Protocol for prospective observation, reform enforcement, and regulatory escalation. Each facility is subject to smart contract triggers, DAO voting logic, and public dashboard transparency. No biospecimens are retained; all data is notarized via SHA-256 hash anchors and integrated into NFT fiscal declarations and validator ballot modules. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population consists of U.S. healthcare facilities identified through coalition-backed validator affidavits and whistleblower declarations. These facilities exhibit patterns of fraud, kickback schemes, and supply chain vulnerabilities. The population is monitored prospectively via smart contract triggers, DAO voting, and public dashboard metrics.
Key inclusion criteria (3 listed)
- Facility has documented billing, compliance, or procurement irregularities.
- Facility participates in coalition validator onboarding and SHA-256 protocol enrollment.
- Facility provides access to billing, procurement, and whistleblower-anchored datasets for auditing.
Key exclusion criteria (4 listed)
- Facility refuses validator onboarding or coalition integration.
- Facility lacks traceable procurement or compliance records.
- Facility has no whistleblower declaration or validation artifact.
- Facility operates outside U.S. jurisdiction or coalition-recognized governance zones.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Validator-Governed Reform & Regulatory Escalation ProtocolAlso: PHX-AFK-US ProtocolThis intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based. | Other | Flagged Healthcare Facilities - Validator Oversight Cohort |
| Coalition-Grade Validator Dashboard Module (CVDM-1)Also: PHX-AFK-US Governance TerminalThe Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains. | Device | Flagged Healthcare Facilities - Validator Oversight Cohort |
| Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)Also: CFPAT-1The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains. | Drug | Flagged Healthcare Facilities - Validator Oversight Cohort |
Primary outcome
Change in Fraudulent Billing and Kickback Incidents Across Enrolled Facilities
Time frame: Baseline to 12 Months Post-Validator Onboarding
Description: This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols. Facilities are assessed using the Unified Impact Index derived from: Historical billing anomalies Validator audit results Whistleblower declarations SHA-256 hash-anchored incident reports Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards. Time Frame: Baseline to 12 Months Post-Validator Onboarding.
1 secondary outcome
Change in Supply-Chain Traceability and Compliance Across Enrolled Facilities
Time frame: Baseline to 12 Months Post-Validator Onboarding
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gavin C Solomon, President & CEO principal investigator
Truway Health, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthcare Fraud Schemes and Kickback Networks, run by Truway Health, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Fraudulent Billing and Kickback Incidents Across Enrolled Facilities (time frame: Baseline to 12 Months Post-Validator Onboarding). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.